A Controlled Trial of CBT for MS Inflammation
CBT 治疗多发性硬化症炎症的对照试验
基本信息
- 批准号:7111692
- 负责人:
- 金额:$ 149.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-01 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:behavioral /social science research tagbiomarkerblood brain barrierclinical researchclinical trialscognitive behavior therapygadoliniumhealth behaviorhuman subjecthuman therapy evaluationimmunologic assay /testinflammationlongitudinal human studymagnetic resonance imagingmemorymultiple sclerosisneuroimagingneuropsychologypatient oriented researchquality of lifestress management
项目摘要
DESCRIPTION (provided by applicant): MS is a frequently disabling autoimmune disease affecting approximately 350,000 people in the United States. It is among the most disabling diseases in the United States, with 81% of all patients out of the workforce. More that two decades of research has consistently shown a relationship between stressful life events (SLEs), in particular non-traumatic family and work stressors, and subsequent clinical exacerbation. Furthermore, we have shown that non-traumatic SLEs increase the risk of the subsequent appearance of new gadolinium enhancing (Gd+) magnetic resonance imaging (MRI) brain lesions, an early marker of MS inflammation and blood-brain barrier (BBB' breakdown. The purpose of this study is to determine the efficacy of cognitive behavioral therapy for MS (CBT. MS), a stress management program we have developed specifically for MS, in reducing the occurrence of new brain lesions in people with relapsing-remitting multiple sclerosis (RRMS). RRMS was selected over other types, because it is the most common form of MS and it is more likely than other types to be associated with clinical exacerbation and Gd+ MRI. One hundred and twelve patients will be enrolled for 2 years. To ensure equivalent medical treatment across patients and treatment arms, all patients will receive neurological care through the University of California, San Francisco (UCSF) MS Center. Patients will be randomly assigned to either CBT-MS or treatment as usual (TAU). The stress management program will consist of 26 weekly group stress management training sessions followed by 12 monthly booster sessions to encourage maintenance of behavioral changes, Because MS exacerbation is episodic, with annual prevalence rates of .61 - 1.68, longer maintenance of behavioral changes will greatly increase the power to detect effects. Patients will be followed for 6 months following cessation of treatment and booster sessions. To encourage retention, TAU patients will be offered 26 weeks of CBT-MS after completing the study. Consistent with Phase II clinical trials in MS, the primary outcome will be Gd+ MRI brain lesions acquired at screening, and months 3, 6, 12, 18, and 24. Secondary neuroimaging outcomes will include T2-weighted MRI and brain parenchymal fraction (BPF). Secondary clinical outcomes will include MS exacerbation rate, progression of disability, and neuropsychological impairment. Quality of life will be examined as a secondary outcome to evaluate clinical utility. We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation.
描述(由申请人提供):MS是一种经常致残的自身免疫性疾病,在美国影响约350,000人。它是美国最具致残性的疾病之一,81%的患者无法工作。二十多年的研究一致表明,压力性生活事件(SLEs),特别是非创伤性家庭和工作压力源与随后的临床恶化之间存在关系。此外,我们已经表明,非创伤性SLE增加了随后出现新的钆增强(Gd+)磁共振成像(MRI)脑损伤的风险,这是MS炎症和血脑屏障(BBB)破坏的早期标志物。本研究的目的是确定认知行为疗法(CBT)治疗MS的疗效。MS),我们专门为MS开发的压力管理计划,在减少复发缓解型多发性硬化症(RRMS)患者新发脑病变的发生方面。选择RRMS而不是其他类型,因为它是MS的最常见形式,并且比其他类型更可能与临床加重和Gd+ MRI相关。112例患者将入组2年。为了确保患者和治疗组之间的等效医疗,所有患者将通过加州大学旧金山弗朗西斯科(UCSF)MS中心接受神经系统护理。患者将被随机分配至CBT-MS或常规治疗(TAU)。压力管理计划将包括26次每周一次的团体压力管理培训课程,随后是12次每月一次的加强课程,以鼓励维持行为变化。由于MS恶化是偶发性的,年患病率为0.61 - 1.68,因此更长时间维持行为变化将大大增加检测效果的能力。患者将在停止治疗和加强治疗后随访6个月。为了鼓励保留,TAU患者将在完成研究后接受26周的CBT-MS治疗。与MS II期临床试验一致,主要结局将是筛选时以及第3、6、12、18和24个月时获得的Gd+ MRI脑病变。次要神经影像学结局将包括T2加权MRI和脑实质分数(BPF)。次要临床结局将包括MS加重率、残疾进展和神经心理学损害。生活质量将作为次要结局进行检查,以评价临床效用。我们还将通过检查SLE与MS炎症的临床和神经影像学标志物之间关系的潜在心理社会、免疫和内分泌介质来增强对机制的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David I Daikh其他文献
David I Daikh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David I Daikh', 18)}}的其他基金
A Controlled Trial of CBT for Multiple Sclerosis Inflammation
CBT 治疗多发性硬化症炎症的对照试验
- 批准号:
7287441 - 财政年份:2003
- 资助金额:
$ 149.94万 - 项目类别:
A Controlled Trial of CBT for Multiple Sclerosis Inflammation
CBT 治疗多发性硬化症炎症的对照试验
- 批准号:
8144984 - 财政年份:2003
- 资助金额:
$ 149.94万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
- 批准号:81101308
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
精神分裂症记忆障碍的脑网络组学研究
- 批准号:91132301
- 批准年份:2011
- 资助金额:350.0 万元
- 项目类别:重大研究计划
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
- 批准号:81072363
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
- 批准号:81060151
- 批准年份:2010
- 资助金额:25.0 万元
- 项目类别:地区科学基金项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Cannabis and Pathogenic Mechanisms influencing Blood Brain Barrier Function in HIV
大麻和影响艾滋病毒血脑屏障功能的致病机制
- 批准号:
10683027 - 财政年份:2023
- 资助金额:
$ 149.94万 - 项目类别:
Relationships between blood-brain barrier breakdown, Alzheimer's disease pathology, and memory in aging
血脑屏障破坏、阿尔茨海默病病理学和衰老记忆之间的关系
- 批准号:
10799538 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Relationships between blood-brain barrier breakdown, Alzheimer's disease pathology, and memory in aging
血脑屏障破坏、阿尔茨海默病病理学和衰老记忆之间的关系
- 批准号:
10387988 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
全球血脑屏障破坏和中风后认知能力下降
- 批准号:
10444660 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Immune cell activation and associated blood brain barrier changes across different stages of Alzheimer's disease
阿尔茨海默病不同阶段的免疫细胞激活和相关血脑屏障变化
- 批准号:
10515907 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
COVID-19-related blood-brain barrier and microstructural brain injury; Sex differences and synergy with Alzheimer's disease risk
COVID-19相关的血脑屏障和脑微结构损伤;
- 批准号:
10584896 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
全球血脑屏障破坏和中风后认知能力下降
- 批准号:
10598120 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Immune cell activation and associated blood brain barrier changes across different stages of Alzheimer's disease
阿尔茨海默病不同阶段的免疫细胞激活和相关血脑屏障变化
- 批准号:
10688122 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Project 2: Protection of Blood-Brain Barrier Function
项目二:血脑屏障功能保护
- 批准号:
10684086 - 财政年份:2022
- 资助金额:
$ 149.94万 - 项目类别:
Develpment of the biomarker for the blood-brain barrier breakdown in multiple sclerosis by exosomal miRNA.
通过外泌体 miRNA 开发多发性硬化症血脑屏障破坏的生物标志物。
- 批准号:
21K15690 - 财政年份:2021
- 资助金额:
$ 149.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists